AB

Alon Ben-Noon

Chief Executive Officer

NeuroSense Therapeutics

NeuroSense Therapeutics Pipeline

DrugIndicationPhase
PrimeCAmyotrophic Lateral Sclerosis (ALS)Phase IIb